SMAP1: The Small ArfGAP 1 Transcript Variant as a Drug Target and Biomarker

Target Name: SMAP1

NCBI ID: G60682

SMAP1

SMAP1: The Small ArfGAP 1 Transcript Variant as a Drug Target and Biomarker

Small ArfGAP 1 (SMAP1) is a gene that encodes a protein involved in the regulation of the cytoskeleton and cell adhesion. It is a member of the ArfGAP family, which includes proteins that are involved in the regulation of a variety of cellular processes, including cytoskeletal organization, cell adhesion, and signaling pathways. SMAP1 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SMAP1 is expressed in a variety of tissues and cells, including muscle cells, neurons, and glial cells. It is involved in the regulation of cytoskeletal organization and in the maintenance of cell-cell adhesion. It has been shown to play a role in a variety of cellular processes, including the regulation of cell division, the assembly and disassembly of organelles, and the regulation of cell signaling pathways.

SMAP1 has also been shown to be involved in the regulation of cellular interactions with the surrounding environment, including the cytoskeleton and the extracellular matrix. It has been shown to interact with a variety of proteins, including the cadherins, which are a family of transmembrane proteins that are involved in cell-cell adhesion.

SMAP1 has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that SMAP1 is involved in the regulation of cell proliferation and has been shown to promote the growth and survival of cancer cells. It has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

SMAP1 has also been identified as a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that SMAP1 levels are elevated in a variety of cancer cells and that they are associated with poor prognosis in cancer patients. It has also been shown to be involved in the regulation of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

SMAP1 has been shown to be involved in the regulation of a variety of cellular processes, including cytoskeletal organization, cell adhesion, and signaling pathways. It has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of SMAP1 in these diseases and to develop effective treatments.

Protein Name: Small ArfGAP 1

Functions: GTPase activating protein that acts on ARF6. Plays a role in clathrin-dependent endocytosis. May play a role in erythropoiesis (By similarity)

The "SMAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets